Anavex Life Sciences Corp (AVXL)

[powerwalker]

Once again, we have an affirmation that 2-73 has therapeutic benefits in early stages of the drug's research:

Recently, an investigational therapy, Anavex 2-73, being assessed in clinical trials for Alzheimer’s disease, was discovered to reinstate the function of injured nerve cells in mouse models of the Parkinson’s disease. Thus, the rise is the development of such drugs is likely to boost the growth of the Parkinson’s disease therapeutics market in the near future.

So, what is the score now ... 50+ positive study results of 2-73 on its recipients (regardless of the disease) vs. ZERO negative results.

Let's bring it home, TGD ... Anavex now!

P.S. Ruby, I could not read the chart you posted ... bad eyes. Is 2-73 listed? TIA

P.P.S. So, Doc, when you question the cash resources of Anavex to conduct the trials, why do you continually doubt its ability to meet the cash required, but not state why, given the new environment of trials in 2018 and beyond? Inquiring minds want to know your logic ... reasonable or not!